CervoMed Inc. (CRVO)
NASDAQ: CRVO · Real-Time Price · USD
8.82
-0.56 (-5.97%)
May 7, 2025, 4:00 PM EDT - Market closed

Company Description

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer’s diseases, frontotemporal dementia, and ischemic stroke recovery.

The company develops EIP200 for central nervous system which is in preclinical trials. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

CervoMed Inc.
CervoMed logo
Country United States
Founded 2001
Industry Biotechnology
Sector Healthcare
Employees 15
CEO John Alam

Contact Details

Address:
20 Park Plaza, Suite 424
Boston, Massachusetts 02116
United States
Phone 617 744 4400
Website cervomed.com

Stock Details

Ticker Symbol CRVO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001053691
CUSIP Number 15713L109
ISIN Number US15713L1098
Employer ID 30-0645032
SIC Code 2834

Key Executives

Name Position
Dr. John J. Alam M.D. Co-Founder, Chief Executive Officer, President and Director
Dr. Sylvie L. Gregoire Pharm.D. Co-Founder and Director
William Robert Elder J.D. Chief Financial Officer and General Counsel
Dr. Robert J. Cobuzzi Jr., Ph.D. Chief Operating Officer and Director
Kelly Blackburn M.H.A. Executive Vice President of Clinical Development
Dr. Mark A. De Rosch Ph.D. SVice President of Regulatory and Government Affairs & Program Management
Dr. Claudia Ordonez M.D. Senior Vice President of Medical Science

Latest SEC Filings

Date Type Title
May 7, 2025 SCHEDULE 13G Filing
Apr 30, 2025 ARS Filing
Apr 29, 2025 DEF 14A Other definitive proxy statements
Apr 18, 2025 8-K Current Report
Apr 7, 2025 8-K Current Report
Mar 18, 2025 8-K Current Report
Mar 17, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 17, 2025 10-K Annual Report
Mar 11, 2025 8-K Current Report
Mar 10, 2025 8-K Current Report